Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Pharmaceuticals Holding Co., Ltd    601607   CNE000000C82

SHANGHAI PHARMACEUTICALS HOLDING CO., LT

(601607)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shanghai Pharmaceuticals : PROXY FORM OF HOLDERS OF H SHARES FOR USE AT THE 2019 FIRST EXTRAORDINARY GENERAL MEETING

share with twitter share with LinkedIn share with facebook
share via e-mail
10/31/2019 | 04:27am EDT

上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

PROXY FORM OF HOLDERS OF H SHARES FOR USE AT THE

2019 FIRST EXTRAORDINARY GENERAL MEETING

I/We (Note 1)

of

being shareholder(s) ofH Shares (Note 2) of Shanghai Pharmaceuticals Holding Co., Ltd.

(the "Company"), hereby appoint the Chairman of the Meeting or (Note 3) of

as my/our proxy to attend and vote for me/us and on my/our behalf at the 2019 First Extraordinary General Meeting (the "EGM") to be held at Meeting Room 601, 6th Floor of Affiliated Building, Maple International Building Two, 450 Fenglin Road, Xuhui District, Shanghai, PRC on 18 December 2019 at 13:00 and any adjournment thereof. I/We direct that my/our votes be cast on the resolutions set out in the Notice of the EGM dated 1 November 2019 as indicated in the appropriate boxes below, and, if no such indication is given, as my/our proxy thinks fit.

Special Resolutions

For (Note 4)

Against (Note 4)

Abstain (Note 4)

  1. Proposal regarding the Proposed Adoption of the 2019 Share Option Scheme
  2. Proposal regarding the Assessment Management Measure for the Implementation of the 2019 Share Option Scheme
  3. Proposal regarding the Proposed Authorization to the Board to Deal With Relevant Matters in Relation to the 2019 Share Option Scheme

Date:

2019

Signature (Note 5):

Notes:

  1. Please insert the full name(s) (in Chinese or in English) and address(es) (must be the same address(es) as shown in the register of members) as shown in the register of members of the Company in block letters.
  2. Please insert the number of shares registered in your name(s) to which the Proxy Form relates. This Proxy Form will be deemed to relate to such number of shares inserted. If no number is inserted, this Proxy Form will be deemed to relate to all the shares in the Company registered in your name(s).
  3. If any proxy other than the chairman of the meeting is preferred, delete the words "the Chairman of the Meeting or" and insert the name and address of the proxy desired in the space provided. A shareholder may appoint one or more proxies to attend and vote in his stead. A proxy need not be a shareholder of the Company.
  4. IMPORTANT: if you wish to vote for any resolution, please tick in the box marked "For". If you wish to vote against any resolution, please tick in the box marked "Against". If you wish to abstain for vote, please tick in the box marked "Abstain". If you do not indicate how you wish your proxy to vote, your proxy will be entitled to exercise his discretion.
  5. This Proxy Form must be signed by you or your attorney duly authorised in writing or, or if the appointer is a legal entity, either under seal or signed by a director or a duly authorized attorney. If that instrument is signed by an attorney of the appointer, a proxy form authorizing that attorney to sign or other document of authorization must be notarised. Any alteration made to this Proxy Form must be duly initiated by the person who signs it.
  6. In case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of votes of the other joint holder(s) and for this purpose seniority will be determined by the order in which the names stand in the H Share register of members of the Company.
  7. To be valid, this Proxy Form, together with notarised power of attorney or other authority, must be delivered to the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for the purpose of holders of H shares of the Company) not less than 24 hours before the time for holding the EGM or the time appointed for voting by poll.
  8. Completion and delivery of this Proxy Form will not preclude you from attending and voting at the EGM in person if you so wish.
  • For identification purpose only

Disclaimer

Shanghai Pharmaceuticals Holding Co. Ltd. published this content on 31 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 October 2019 09:26:05 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHANGHAI PHARMACEUTICALS H
01/22ENZYMATICA PUBL : signs agreement with Keyuan Trade for China
AQ
2019SHANGHAI PHARMACEUTICALS : Grant of share options under the share option scheme
PU
2019SHANGHAI PHARMACEUTICALS : Results of the extraordinary general meeting, a share..
PU
2019SHANGHAI PHARMACEUTICALS : Notification Letter and Change Request Form to Regist..
PU
2019SHANGHAI PHARMACEUTICALS : Reply slip for holders of h share attending the 2019 ..
PU
2019SHANGHAI PHARMACEUTICALS : Form of proxy of holders of h shares for use at the 2..
PU
2019SHANGHAI PHARMACEUTICALS : Proxy form of the independent non-executive director ..
PU
2019SHANGHAI PHARMACEUTICALS : Notice of 2019 second h share class meeting
PU
2019SHANGHAI PHARMACEUTICALS : Reply slip for holders of h share attending the 2019 ..
PU
2019SHANGHAI PHARMACEUTICALS : Proxy form of holders of h shares for use at the 2019..
PU
More news
Financials (CNY)
Sales 2020 205 B
EBIT 2020 6 950 M
Net income 2020 4 567 M
Debt 2020 19 675 M
Yield 2020 2,51%
P/E ratio 2020 12,1x
P/E ratio 2021 10,7x
EV / Sales2020 0,33x
EV / Sales2021 0,28x
Capitalization 48 585 M
Chart SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Duration : Period :
Shanghai Pharmaceuticals Holding Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 20,66  CNY
Last Close Price 19,51  CNY
Spread / Highest target 34,8%
Spread / Average Target 5,88%
Spread / Lowest Target -32,4%
EPS Revisions
Managers
NameTitle
Da Wei Liu Deputy Chief Executive Officer
Man Cho President & Executive Director
Jun Zhou Chairman
Bo Shen Chief Financial Officer, Executive Director & VP
Keng Xin Member-Supervisory Board
Sector and Competitors